Clinical trials: Diseases of the Urinary System
Urinary Incontinence, Urinary Bladder, Overactive
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder…
- Trial name
- NCT02010788
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 523 people
- Sponsor
- Allergan
Urinary Bladder, Overactive
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder.
- Trial name
- NCT00479505
- Testing
- UK-369,003
- Where
- 52 sites in Australia, Canada and 14 more
- Volunteers
- 275 people
- Sponsor
- Pfizer
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Non-muscle Invasive Bladder Cancer
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer
This study evaluates the tolerability and preliminary anti-tumour effect of alpha1H in adults with non-muscle invasive bladder cancer, who are awaiting transurethral surgery.
- Trial name
- NCT03560479
- Testing
- alpha1H, 7.4 mg/mL, alpha1H, 37 mg/mL, alpha1H, 74 mg/mL
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- Hamlet Pharma AB
Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either…
- Trial name
- NCT07416162
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
BPH (Benign Prostatic Hyperplasia), BPH
INTUPRO in the Treatment of Benign Prostatic Hyperplasia-Related Symptoms
The goal of this clinical trial is to determine whether INTUPRO can improve the quality of life in patients with Benign Prostate Hyperplasia (BPH).
- Conditions
- BPH (Benign Prostatic Hyperplasia), BPH, BPH With Other Lower Urinary Tract Symptoms
- Trial name
- NCT07381127
- Testing
- INTUPRO ionic fluid
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- inTumo Therapeutics, Inc.
Acute Gouty Arthritis
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult…
- Trial name
- NCT01593527
- Testing
- ACZ885, Triamcinelone acetonide
- Sponsor
- Novartis Pharmaceuticals
Nocturnal Enuresis
Overnight Pant Study for Children With Nocturnal Enuresis
This study will evaluate the in-use tolerance of an absorbent disposable underwear pant developed for children with nocturnal enuresis by assessing adverse events.
- Trial name
- NCT05178641
- Testing
- Ninjamas Pyjama Pants, Participant's Overnight Current Standard of Care
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Metastatic Renal Cell Carcinoma (mRCC)
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
- Trial name
- NCT04175262
- Testing
- sunitinib
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Pfizer
Superficial Bladder Cancer
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
This study is designed to assess the efficacy and safety of DTA-H19/PEI given as six intravesical instillations of 20 mg of plasmid DNA complexed with PEI into the bladder of patients with intermediate risk superficial bladder…
- Trial name
- NCT00595088
- Testing
- BC-819/PEI
- Where
- 6 sites in United States, Israel
- Volunteers
- 47 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD…
- Trial name
- ESSENTIAL (NCT03949894)
- Testing
- Tolvaptan
- Where
- 18 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Kidney Cancer
Virtual 3D Modelling for Improved Surgical Planning of Robotic-assisted Partial Nephrectomy
To establish whether surgical planning using virtual 3D modelling (Innersight 3D) improves the outcome and cost-effectiveness of RAPN, allowing more patients to benefit from minimally-invasive procedures.
- Trial name
- VISP (NCT05109182)
- Testing
- Innersight3D
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Innersight Labs Ltd
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Ureteral Calculi
Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy
Objective: To observe the effect of Ningmitai capsule on ureteral calculi after lithotripsy and evaluate the safety of treatment.
- Trial name
- 3 (NCT06105827)
- Testing
- Control group, Ningmitai capsule, Combined group (Ningmitai plus tamsulosin)
- Volunteers
- 251 people
- Sponsor
- Xintian Pharmaceutical
Kidney Disease, Chronic
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
This randomized, single-blind, proof-of-concept study will investigate the protective effects of early treatment with Mircera in participants with chronic kidney disease on renal disease progression.
- Trial name
- NCT01194154
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 33 sites in Germany
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Urinary Bladder, Overactive
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended…
- Trial name
- NCT01054222
- Testing
- Fesoterodine
- Where
- 3 sites in Portugal
- Volunteers
- 31 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT04626479
- Testing
- Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan
- Where
- 55 sites in United States, Australia and 12 more
- Volunteers
- 393 people
- Sponsor
- Merck Sharp & Dohme LLC
End-Stage Renal Disease
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
- Trial name
- NCT05880537
- Testing
- Nexeon Arterial Venous Allograft
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- LifeNet Health
Covid19, Stage 1 Acute Kidney Injury
Phase 2a MIB-626 vs. Placebo COVID-19
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by…
- Trial name
- NCT05038488
- Testing
- MIB-626, Home Treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Metro International Biotech, LLC
End Stage Renal Disease
Xeltis Hemodialysis Access Graft (aXess) US Study
A multi-center, prospective, single-arm, non-randomized, staged, pivotal clinical study to evaluate the safety and performance of the aXess graft in subjects aged 18 and above, diagnosed with end-stage kidney disease, and…
- Trial name
- NCT06494631
- Testing
- Xeltis Hemodialysis Access (aXess) graft
- Where
- 7 sites in United States
- Volunteers
- 140 people
- Sponsor
- Xeltis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.